Boston Partners
AKBA icon

Boston Partners’s Akebia Therapeutics AKBA Stock Holding History

Boston Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-70,003
Closed -$531K – 656
2020
Q1 		$531K Sell
70,003
-169,815
-71% -$1.32M ﹤0.01% 592
2019
Q4 		$1.52M Sell
239,818
-61,785
-20% -$294K ﹤0.01% 538
2019
Q3 		$1.18M Buy
301,603
+55,337
+22% +$237K ﹤0.01% 571
2019
Q2 		$1.19M Sell
246,266
-36,778
-13% -$209K ﹤0.01% 602
2019
Q1 		$2.32M Buy
283,044
+3,666
+1% +$25.2K ﹤0.01% 523
2018
Q4 		$1.54M Buy
+279,378
New +$2.19M ﹤0.01% 588

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Boston Partners's AKBA Position: Q2 2020 in Review

Boston Partners sold out of Akebia Therapeutics (AKBA) in Q2 2020, closing a stake of 70,003 shares — an estimated $531K sold.

Boston Partners first reported a position in AKBA in Q4 2018 and held it in 6 quarters. The position peaked at $2.32M in Q1 2019. 189 funds tracked by Wall St. Rank hold AKBA as of Q2 2020.

  • Boston Partners reported no remaining Akebia Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Boston Partners sold 70,003 Akebia Therapeutics shares in Q2 2020, an estimated $531K.
  • Boston Partners first reported a position in Akebia Therapeutics in Q4 2018 and held it in 6 quarters.
  • Boston Partners's Akebia Therapeutics position peaked at $2.32M in Q1 2019.
  • 189 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2020.

Based on Boston Partners's 13F filing for Q2 2020, filed 12 Aug 2020.